Source: Υπουργείο Υγείας (CY) Revision Year: 2011 Publisher: Medochemie Ltd, p.o box 51409, Limassol, Cyprus
Zafibral.
| Pharmaceutical Form |
|---|
|
Film-coated tablet for oral administration. “Zafibral” 200 mg are yellow, round, convex film coated tablets, with a diameter of 9.5 mm. |
Each tablet contains bezafibrate 200 mg.
For excipients, see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bezafibrate |
Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism. |
| List of Excipients |
|---|
|
“Zafibral” tablets also contain microcrystallinEcellulose, maizEstarch, povidone, sodium starch glycollate, colloidal anhydrous silica, and magnesium stearate. ThEfilm coating contains Opadry Yellow OY-6137 which consists of hydroxypropylmethylcellulose, macrogol 400, titanium dioxide (E171), iron oxidEyellow (E172), Sunset yellow (E110), and quinolinEyellow (E104). |
PVC-Al blisters.
Boxes of 50, 100, 200 and 1000 tablets.
Medochemie Ltd, p.o box 51409, Limassol, Cyprus
13763
First authorisation: 8 October 1992
| Drug | Countries | |
|---|---|---|
| ZAFIBRAL | Cyprus, Hong Kong, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
